ASMB vs VIR
ASMB: Assembly Biosciences is a clinical-stage biotech developing small-molecule therapies to treat chronic viral and liver diseases, supported by a strategic partnership with Gilead Sciences. VIR: A clinical-stage immunology company developing innovative therapies to combat serious infectious diseases.
Side-by-side fundamentals
| Metric | ASMB | VIR | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $22.82 | $11.12 | |
| Market cap | $465M | $1.9B | |
| Net margin FY2025, SEC XBRL | -8.5% | -638.9% | ASMB higher |
| Operating margin FY2025, SEC XBRL | -16.8% | -699.2% | ASMB higher |
| ROE FY2025, SEC XBRL | -3.0% | -57.2% | ASMB higher |
| ROA FY2025, SEC XBRL | -2.4% | -43.7% | ASMB higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-09-03 | +121.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | n/a | -65.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.02 | 1.53 | |
| 1-year return as of 2026-10-08 close | -10.5% | +83.8% | VIR higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.